Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke

References

• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci US 2003;100:928–33.
   PubMed Web of Science ®Google Scholar
• Saavedra YG, Zhang J, Seidah NG. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation. PloS One 2013;8:e72113.
   PubMed Web of Science ®Google Scholar
• Mayne J, Ooi TC, Raymond A, et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Disease 2013;12:70.
   PubMed Web of Science ®Google Scholar
• Norata GD, Garlaschelli K, Grigore L, et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177–82.
   PubMed Web of Science ®Google Scholar
• Chen YQ, Troutt JS, Konrad RJ. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids 2014;49:445–55.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Lee YH, Park SW, et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism 2013;62:845–50.
   PubMed Web of Science ®Google Scholar
• Slimani A, Harira Y, Trabelsi I, et al. Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort. J Mol Neurosci 2014;53:150–7.
   PubMed Web of Science ®Google Scholar
• Li S, Guo YL, Xu RX, et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiology 2014;174:863–4.
   PubMed Web of Science ®Google Scholar
• Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PloS One 2007;2:e1043.
   PubMed Web of Science ®Google Scholar
• Farnier M. PCSK9: From discovery to therapeutic applications. Arch Cardiovascular Diseases 2014;107:58–66.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discovery 2012;11:367–83.
   PubMed Web of Science ®Google Scholar
• Benjannet S, Saavedra YG, Hamelin J, et al. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem 2010;285:40965–78.
   PubMed Web of Science ®Google Scholar
• Zhang DW, Garuti R, Tang WJ, et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 2008;105:13045–50.
   PubMed Web of Science ®Google Scholar
• Lo Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011;12:1300–5.
   PubMed Web of Science ®Google Scholar
• McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009;284:10561–70.
   PubMed Web of Science ®Google Scholar
• Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genetics 2004;114:349–53.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14:413–9.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012;223:394–400.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Tuakli Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genetics 2006;79:514–23.
   PubMed Web of Science ®Google Scholar
• Slimani A, Jelassi A, Jguirim I, et al. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis 2012;222:158–66.
   PubMed Web of Science ®Google Scholar
• Fasano T, Sun XM, Patel DD, et al. Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells. Atherosclerosis 2009;203:166–71.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228:18–28.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Dev Ther 2013;7:1135–48.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Cerda A, Hirata MH, et al. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. J Clin Lipidology 2014;8:256–64.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283:2363–72.
   PubMed Web of Science ®Google Scholar
• Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279:48865–75.
   PubMed Web of Science ®Google Scholar
• Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arteriosclerosis Thrombosis Vascular Biol 2011;31:785–91.
   PubMed Web of Science ®Google Scholar
• Choi S, Aljakna A, Srivastava U, et al. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Disease 2013;12:112.
   PubMed Web of Science ®Google Scholar
• Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll. Cardiology 2013;62:1131–43.
   PubMed Web of Science ®Google Scholar
• Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092–104.
   PubMed Web of Science ®Google Scholar
• Cure MC, Tufekci A, Cure E, et al. Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. Ann Indian Acad Neurology 2013;16:498–503.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Felicioni L, Sarzani R, et al. A unique microRNA signature associated with plaque instability in humans. Stroke 2011;42:2556–63.
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. New England J Med 2011;364:226–35.
   PubMed Web of Science ®Google Scholar
• Nichols TC. Bad cholesterol breaking really bad. Blood 2013;122:3551–3.
   PubMed Web of Science ®Google Scholar
• Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012;125:894–901.
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012;220:381–6.
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227–76.
   PubMed Web of Science ®Google Scholar
• Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Therapeutic Targets 2009;13:19–28.
   PubMed Web of Science ®Google Scholar
• Urban D, Poss J, Bohm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll. Cardiology 2013;62:1401–8.
   PubMed Web of Science ®Google Scholar
• Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med 2012;30:931–8.
   PubMed Web of Science ®Google Scholar
• Wu CY, Tang ZH, Jiang L, et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 2012;359:347–58.
   PubMed Web of Science ®Google Scholar
• Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010;584:701–6.
   PubMed Web of Science ®Google Scholar
• Sharotri V, Collier DM, Olson DR, et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem 2012;287:19266–74.
   PubMed Web of Science ®Google Scholar
• Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013;81:264–72.
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Secondary stroke prevention. Lancet Neurology 2014;13:178–94.
   PubMed Web of Science ®Google Scholar
• Tsai NW, Lee LH, Huang CR, et al. Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care 2014;18:R16.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ballinger DG, Stokowski R, et al. Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med 2012;4:57.
   PubMed Web of Science ®Google Scholar
• Ebrahim S, Sung J, Song YM, et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006;333:22.
   PubMed Web of Science ®Google Scholar
• Saposnik G, Fonarow GC, Pan W, et al. Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from get with the guidelines-stroke 2003 to 2012. Stroke 2014;45:3343–51.
   PubMed Web of Science ®Google Scholar
• Han D, Ma J, Zhang X, et al. Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations. Med Sci Monitor 2014;20:1758–67.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders 2014;14:121.
   PubMed Web of Science ®Google Scholar
• Marais DA, Blom DJ, Petrides F, et al. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidology 2012;23:511–7.
   PubMed Web of Science ®Google Scholar